Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1996-12-5
|
pubmed:abstractText |
Body wasting, particularly loss of body cell mass, is an increasingly prevalent acquired immunodeficiency syndrome (AIDS)-defining condition and is an independent risk factor for death in patients infected with the human immunodeficiency virus (HIV). Treatment with growth hormone for 7 days resulted in weight gain and nitrogen retention, but the long-term effects of this treatment in patients with HIV-associated wasting are not known.
|
pubmed:grant | |
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0003-4819
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
125
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
873-82
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8967667-Adult,
pubmed-meshheading:8967667-Body Composition,
pubmed-meshheading:8967667-Body Water,
pubmed-meshheading:8967667-Bone Density,
pubmed-meshheading:8967667-Female,
pubmed-meshheading:8967667-HIV Wasting Syndrome,
pubmed-meshheading:8967667-Human Growth Hormone,
pubmed-meshheading:8967667-Humans,
pubmed-meshheading:8967667-Male,
pubmed-meshheading:8967667-Middle Aged,
pubmed-meshheading:8967667-Patient Dropouts,
pubmed-meshheading:8967667-Quality of Life,
pubmed-meshheading:8967667-Treatment Outcome,
pubmed-meshheading:8967667-Weight Gain
|
pubmed:year |
1996
|
pubmed:articleTitle |
Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group.
|
pubmed:affiliation |
San Francisco General Hospital, CA 94110, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|